Risankizumab for pityriasis rubra pilaris
ContributorsBrocco, Elise
Published inClinical and experimental dermatology, vol. 46, no. 7, p. 1322-1324
Publication date2021-10
First online date2021-06-13
Keywords
- Adult
- Antibiotics, Antitubercular / therapeutic use
- Antibodies, Monoclonal / administration & dosage
- Antibodies, Monoclonal / therapeutic use
- Female
- Humans
- Injections, Subcutaneous
- Latent Tuberculosis / complications
- Latent Tuberculosis / drug therapy
- Pityriasis Rubra Pilaris / complications
- Pityriasis Rubra Pilaris / drug therapy
- Pityriasis Rubra Pilaris / pathology
- Rifampin / therapeutic use
Affiliation entities
Research groups
Citation (ISO format)
BROCCO, Elise, LAFFITTE, Emmanuel Alexis. Risankizumab for pityriasis rubra pilaris. In: Clinical and experimental dermatology, 2021, vol. 46, n° 7, p. 1322–1324. doi: 10.1111/ced.14715
Main files (1)
Article (Published version)
Identifiers
- PID : unige:159812
- DOI : 10.1111/ced.14715
- PMID : 33914925
Additional URL for this publicationhttps://onlinelibrary.wiley.com/doi/10.1111/ced.14715
Journal ISSN0307-6938
